{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:28:24Z","timestamp":1793726904598,"version":"4.6.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7212029"],"award-info":[{"award-number":["7212029"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jneuroim.2021.577790","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:49:58Z","timestamp":1639655398000},"page":"577790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis"],"prefix":"10.1016","volume":"363","author":[{"given":"Jia","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577790_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0010","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s13760-015-0479-z","article-title":"Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review","volume":"115","author":"B\u0103la\u015fa","year":"2015","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0025","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2021.577790_bib382","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Marignier R: treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/imj.12207","article-title":"Experience with low-dose rituximab in off-label indications at two tertiary hospitals","volume":"43","author":"Chay","year":"2013","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","article-title":"The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in western China","volume":"39","author":"Chen","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0050","first-page":"125","article-title":"Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs (New York, N.Y.)"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0060","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0065","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101413","article-title":"Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia","volume":"36","author":"Drulovic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14728214.2020.1803828","article-title":"Emerging drugs for the treatment of neuromyelitis optica","volume":"25","author":"Duchow","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0085","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: a systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0100","first-page":"18","article-title":"Efficacy and safety of rituximab in neuromyelitis optica: review of evidence","volume":"22","author":"Etemadifar","year":"2017","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0105","first-page":"461","article-title":"Clinical evaluation of rituximab treatment for neuromyelitis optica","volume":"30","author":"Fernandez-Megia","year":"2015","journal-title":"Neurologia"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1590\/0004-282x-anp-2020-0041","article-title":"Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders","volume":"79","author":"Gomes","year":"2021","journal-title":"Arq. Neuro-Psiquiat."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2013.02.024","article-title":"Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases","volume":"328","author":"Gredler","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040371","article-title":"Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis","volume":"10","author":"Han","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0130","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0135","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0145","first-page":"9","article-title":"Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China","author":"Huang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0150","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","article-title":"Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders","volume":"324","author":"Ip","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0160","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0165","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0185","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0195","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with Neuromyelitis Optica","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0200","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0205","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102109","article-title":"Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"42","author":"Lim","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101933","article-title":"A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders","volume":"40","author":"Lu","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102484","article-title":"Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: a meta-analysis of real-world studies","volume":"46","author":"Luo","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0240","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0245","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0250","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0255","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0260","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0265","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0270","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","article-title":"Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica","volume":"22","author":"Qiu","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0275","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0280","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","article-title":"Clinical pharmacology and pharmacogenetics of thiopurines","volume":"64","author":"Sahasranaman","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0285","first-page":"155","article-title":"Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: a prospective observation in Iranian cases","volume":"11","author":"Seyed","year":"2020","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0290","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0295","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2017.03.051","article-title":"Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy","volume":"377","author":"Shi","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0300","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0305","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0315","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0320","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0325","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0330","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0335","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0883073814553974","article-title":"Prolonged remission in neuromyelitis optica following cessation of rituximab treatment","volume":"30","author":"Weinfurtner","year":"2015","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0340","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0345","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0350","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0355","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577790_bb0360","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0365","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0370","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0375","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","author":"Zhang","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577790_bb0380","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.msard.2018.12.038","article-title":"Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821003179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821003179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:40:17Z","timestamp":1759048817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821003179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":76,"alternative-id":["S0165572821003179"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577790","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577790"}}